AP2007004227A0 - Novel compounds as GLP-1 agonists - Google Patents

Novel compounds as GLP-1 agonists

Info

Publication number
AP2007004227A0
AP2007004227A0 AP2007004227A AP2007004227A AP2007004227A0 AP 2007004227 A0 AP2007004227 A0 AP 2007004227A0 AP 2007004227 A AP2007004227 A AP 2007004227A AP 2007004227 A AP2007004227 A AP 2007004227A AP 2007004227 A0 AP2007004227 A0 AP 2007004227A0
Authority
AP
ARIPO
Prior art keywords
glp
agonists
novel compounds
novel
compounds
Prior art date
Application number
AP2007004227A
Other languages
English (en)
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Rajesh H Bahekar
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of AP2007004227A0 publication Critical patent/AP2007004227A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AP2007004227A 2005-05-05 2006-05-04 Novel compounds as GLP-1 agonists AP2007004227A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN558MU2005 2005-05-05
IN645MU2005 2005-05-31
PCT/IN2006/000154 WO2007017892A2 (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists

Publications (1)

Publication Number Publication Date
AP2007004227A0 true AP2007004227A0 (en) 2007-12-31

Family

ID=37727716

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004227A AP2007004227A0 (en) 2005-05-05 2006-05-04 Novel compounds as GLP-1 agonists

Country Status (12)

Country Link
EP (1) EP1891106A2 (no)
JP (1) JP2008540402A (no)
KR (1) KR20080021636A (no)
AP (1) AP2007004227A0 (no)
AU (1) AU2006277557A1 (no)
BR (1) BRPI0612471A2 (no)
CA (1) CA2606894A1 (no)
EA (1) EA200702419A1 (no)
IL (1) IL187105A0 (no)
MX (1) MX2007013655A (no)
NO (1) NO20075618L (no)
WO (1) WO2007017892A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
EP2084182B1 (en) * 2006-10-03 2013-08-28 Cadila Healthcare Limited Antidiabetic compounds
KR101277560B1 (ko) * 2007-12-11 2013-06-25 카딜라 핼쓰캐어 리미티드 글루카곤 안타고니스트 활성 및 ｇｌｐ-1 아고니스트 활성의 펩티드 유사체
CN101903400B (zh) * 2007-12-11 2013-12-18 霍夫曼-拉罗奇有限公司 使用固相和液相组合技术的促胰岛素肽合成
CN102414220A (zh) * 2009-05-01 2012-04-11 霍夫曼-拉罗奇有限公司 使用固相和液相组合技术的促胰岛素肽合成
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
WO2014127120A1 (en) 2013-02-15 2014-08-21 Mayo Foundation For Medical Education And Research Insulin secreting polypeptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
GB0024428D0 (en) * 2000-10-05 2000-11-22 King S College Absorption enhancers
AU2002317599B2 (en) * 2001-07-31 2008-04-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GLP-1 exendin-4 peptide analogs and uses thereof
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
AU2003200839B2 (en) * 2002-01-08 2008-12-11 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
AU2005211755B2 (en) * 2004-02-11 2012-03-15 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin

Also Published As

Publication number Publication date
EP1891106A2 (en) 2008-02-27
WO2007017892A2 (en) 2007-02-15
AU2006277557A1 (en) 2007-02-15
BRPI0612471A2 (pt) 2016-09-06
EA200702419A1 (ru) 2008-04-28
NO20075618L (no) 2008-01-30
CA2606894A1 (en) 2007-02-15
KR20080021636A (ko) 2008-03-07
JP2008540402A (ja) 2008-11-20
MX2007013655A (es) 2008-01-24
IL187105A0 (en) 2008-02-09
WO2007017892A3 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
AP2007004171A0 (en) Novel compounds
EP1868612A4 (en) NOVEL CONNECTIONS
EP1868611A4 (en) NOVEL CONNECTIONS
AP2007004227A0 (en) Novel compounds as GLP-1 agonists
GB0503955D0 (en) Novel compounds
EP1869026A4 (en) NEW CONNECTIONS
GB0500140D0 (en) Novel compounds
ZA200709471B (en) Novel compounds as GLP-I agonists
GB0503126D0 (en) Novel compounds
GB0501959D0 (en) Novel compounds
GB0521922D0 (en) Novel compounds
GB0504095D0 (en) Novel compounds
GB0507708D0 (en) Novel compounds
GB0503155D0 (en) Novel compounds
GB0503142D0 (en) Novel compounds
GB0503135D0 (en) Novel compounds
GB0503134D0 (en) Novel compounds
GB0503133D0 (en) Novel compounds
GB0503132D0 (en) Novel compounds
GB0503131D0 (en) Novel compounds
GB0503130D0 (en) Novel compounds
GB0503129D0 (en) Novel compounds
GB0503127D0 (en) Novel compounds
GB0507700D0 (en) Novel compounds
GB0503123D0 (en) Novel compounds